BASF Prepares Agri Unit for IPO, Sparking Hopes of a €30 Billion Valuation and a Stock Revaluation

Inside BASF’s Plan to Take Its Agri Giant Public by 2027

Chemicals giant BASF is moving quickly to bring its agricultural solutions business to the stock market, with a target IPO date as early as the first half of 2027. The unit—which makes crop protection products and seeds—generated around €10 billion in revenue and €2 billion in adjusted profit last year, making it one of the group’s most reliable cash generators. BASF intends to sell only a minority stake, retaining control while raising fresh capital to pay down debt.

Analysts now estimate the division could be worth between €20 billion and €30 billion. When set against BASF’s current market capitalization of around €44 billion, that figure stands out: the agri business contributed roughly one-third of group profit, yet its potential valuation equals half—or even two-thirds—of the entire group’s value. The arithmetic implies that the remaining chemicals operations are deeply undervalued.

CEO Markus Kamieth, who has made slimming the conglomerate a priority, sees the IPO as a way to strip away the conglomerate discount that has weighed on BASF stock for years. The agricultural listing is the latest step in a broader restructuring that has already included the sale of the coatings unit to Carlyle and a sharper focus on basic chemicals, plastics and selected performance materials.

The agricultural business also stands out because it carries none of the legal and reputational baggage that has dogged rival Bayer’s Monsanto acquisition. That clean profile could attract investors looking for exposure to global agriculture without the risk of Roundup litigation—another factor that could support a rich IPO valuation and, by extension, a rerating of the parent.

The Valuation Puzzle: How a €30 Billion Agri Unit Could Unlock BASF’s True Worth

Why the Conglomerate Discount Matters

For years, BASF’s broad portfolio has confused investors and led to a discount versus more focused peers. By floating a minority stake in the agricultural unit, Kamieth forces the market to see the unit’s real value. The IPO will create a standalone listed entity whose earnings, margins and balance sheet are fully transparent. If that entity trades at a premium to the implicit value assigned by the conglomerate’s current share price, the parent’s stock has room to rise as the discount closes.

The Valuation Math

A €30 billion valuation for the agri unit would leave BASF’s remaining operations—which still generate about two-thirds of group profit—at an implied price of just €14 billion. That gap is hard to justify on earnings power alone. Even a more conservative €20 billion tag would show that the market prices BASF’s other assets at roughly half their true earning capacity. The IPO therefore acts as a reality check: once a liquid market price exists, the parent cannot trade at a persistent discount without raising questions.

A Rival Overhang That Benefits BASF

Investors scarred by Bayer’s Monsanto headaches may find a welcome alternative in a pure-play agricultural business with no litigation hangover. BASF’s crop science arm has grown steadily without major scandals, and the IPO could attract funds that want agricultural exposure but have avoided the sector because of Roundup-related uncertainties. That demand could lift the valuation of the new stock and, by extension, raise the floor for BASF shares.

Key Milestones for BASF Shareholders to Watch

Key Dates and Triggers for BASF Shareholders

• Look for a formal IPO intention-to-float filing in early 2027 – BASF has indicated a first-half timeframe and is already hiring investor-relations staff.
• When the prospectus emerges, scrutinize the targeted free float and the valuation range. A number at the high end of the €20–30 billion estimates would signal that the remaining chemicals business is severely undervalued.
• The IPO proceeds are earmarked for debt reduction; track BASF’s post-IPO net debt and leverage metrics to gauge whether the balance sheet boost supports a higher valuation multiple.
• The current dividend, yielding 4.3%, looks stable if cash flows hold, but a successful deal could shift the investment case from a high-yield story to one of capital appreciation as the conglomerate discount unwinds.